Moderna, Inc. Form 8-K Summary
Business Context and Reporting Period
This filing is a Current Report on Form 8-K dated November 12, 2025, regarding Moderna, Inc. (MRNA). The report details the results of a Special Meeting of Shareholders held on November 12, 2025, where a quorum was present.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders approved two proposals at the Special Meeting:
- Proposal 1: Approval of a one-time stock option exchange program for non-Executive Committee employees.
- Proposal 2: Approval to adjourn the Special Meeting to a later date if necessary to permit further solicitation of proxies.
Voting Results:
| Proposal | Votes For | Votes Against | Abstain |
|---|---|---|---|
| Option Exchange Program | 231,049,158 | 6,167,159 | 250,409 |
| Adjournment Authority | 223,991,059 | 13,198,386 | 277,281 |
There were no broker non-votes recorded for either proposal.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the final vote counts.
Key Facts for Investor Verification
- Shareholders approved a one-time stock option exchange program specifically for non-Executive Committee employees.
- The approval margin for the option exchange was approximately 97.4% of votes cast (For vs. Against).
- Shareholders granted the board authority to adjourn the meeting if needed to secure additional votes, though the primary proposal passed without adjournment.
- No financial performance data or strategic updates were included in this specific filing.